{"abstract": "Bristol-Myers Squibb said on Tuesday it had agreed to acquire ZymoGenetics, the maker of a hepatitis C drug the companies were jointly developing, for $885 million.", "web_url": "https://dealbook.nytimes.com/2010/09/08/bristol-myers-agrees-to-acquire-zymogenetics/", "snippet": "Bristol-Myers Squibb said on Tuesday it had agreed to acquire ZymoGenetics, the maker of a hepatitis C drug the companies were jointly developing, for $885 million.", "lead_paragraph": "Bristol-Myers Squibb said on Tuesday it had agreed to acquire ZymoGenetics, the maker of a hepatitis C drug the companies were jointly developing, for $885 million, Bloomberg News reported.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Bristol-Myers Agrees to Acquire ZymoGenetics", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2010-09-08T06:15:26+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/7b3d6ab8-331b-5d3e-a13c-a9f4cd828ddc", "word_count": 135, "uri": "nyt://article/7b3d6ab8-331b-5d3e-a13c-a9f4cd828ddc"}